Vertex Pharmaceuticals Incorporated VX1.DE · Stock Open Vertex Pharmaceuticals Incorporated in new tab
Vertex Pharmaceuticals Incorporated Analysis (VX1.DE)
Is Vertex Pharmaceuticals Incorporated a good investment? Vertex Pharmaceuticals Incorporated (VX1.DE) is currently trading at 446.40 EUR.
In terms of valuation, the stock trades at a P/E ratio of 30.90. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Vertex Pharmaceuticals Incorporated is expected to release its next earnings report on Nov. 2, 2026.
Investor FAQ
Does Vertex Pharmaceuticals Incorporated pay a dividend?
No, it does not currently pay a dividend.
What asset class is Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 2, 2026. The company currently has a trailing EPS of 15.00.
Company Profile
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Community Discussion